Roquefort Investments PLC ( (GB:ROQ) ) has issued an announcement.
Roquefort Therapeutics PLC announced that its Executive Chairman, Stephen West, and CEO, Ajan Reginald, have purchased additional ordinary shares in the company. These acquisitions indicate strong insider confidence in the company’s strategic direction and its potential growth in the competitive fields of immunology and oncology, potentially reassuring stakeholders of the company’s commitment to advancing its innovative therapeutic solutions.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing first-in-class drugs targeting the immunology and oncology markets. Their portfolio includes five novel, patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies, RNA and mRNA therapeutics, STAT-6 siRNA therapeutics, and MK cell therapy, all aimed at offering best-in-class solutions.
YTD Price Performance: -6.17%
Average Trading Volume: 1,444,420
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £5.16M
Find detailed analytics on ROQ stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com